Topical EDTA Chelator Formulation for Age-Related Cataract Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related cataracts are invasive and ineffective, with no FDA-approved pharmacological therapies available, leading to significant vision impairment and blindness, particularly due to the inability of chelator molecules to permeate biological tissues and cell membranes effectively.
Innovation Solution
A topical formulation containing ethylenediaminetetraacetic acid disodium (EDTA) as a chelating agent, combined with permeation enhancers like methylsulfonylmethane (MSM), propylene glycol, and hydroxyethyl cellulose, to target intracellular iron and calcium, thereby slowing down cataract progression and improving visual function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chelator molecules are used to target intracellular iron and calcium, then therapeutic effectiveness is improved, but the ability to permeate biological tissues and cell membranes is insufficient
Solution Approach 1:
The patent uses permeation enhancers (such as cyclodextrins, liposomes, or cell-penetrating peptides) as intermediary carriers to facilitate the transport of chelator molecules across biological membranes. These intermediaries enable the chelators to reach intracellular targets (iron and calcium) that would otherwise be inaccessible, resolving the contradiction between therapeutic effectiveness and membrane permeability.
Solution Approach 2:
The patent modifies the chemical parameters of chelator molecules through conjugation with membrane-permeable moieties or alteration of their molecular structure. This parameter change enables the chelators to penetrate biological tissues and cell membranes while retaining their ability to bind intracellular iron and calcium, thus improving both permeability and therapeutic effectiveness.
2Reliability
If invasive surgical procedures are used to treat cataracts, then vision impairment is corrected, but the treatment becomes invasive with associated risks
Solution Approach 1:
The patent replaces the mechanical surgical intervention (incision, lens removal, and implantation) with a chemical therapy approach. Topically administered chelator molecules chemically bind to and remove excess calcium and iron from the lens, gradually clearing cataracts without physical invasion. This substitution eliminates surgical risks while maintaining vision correction effectiveness.
Solution Approach 2:
The patent enables the body's own physiological processes to clear cataracts by using chelators that facilitate the natural removal of calcium and iron deposits. The topical formulation allows the eye to self-heal through biochemical intervention rather than requiring external surgical intervention, reducing invasiveness while maintaining therapeutic effectiveness.
3Adaptability or versatility
If current pharmacological therapies are used for cataracts, then treatment options are limited, but no FDA-approved therapies are available
Solution Approach 1:
The patent develops composite topical formulations combining multiple active ingredients (chelators such as EDTA or DTPA, permeation enhancers, and protective agents) into a single therapeutic product. This composite approach creates a versatile treatment option that addresses multiple aspects of cataract pathogenesis simultaneously, expanding available treatments while ensuring clinical effectiveness through synergistic interactions among components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively improves contrast sensitivity and visual acuity in patients with early-stage cataracts by reducing light-scattering particles in the lens, providing a non-invasive and clinically significant improvement in visual function.
Implementation Method 1
chelator molecules to permeate biological tissues and cell membranes effectively... target intracellular iron and calcium... reducing light-scattering particles in the lens
Implementation Method 2
the inability of chelator molecules to permeate biological tissues and cell membranes effectively... combined with permeation enhancers like methylsulfonylmethane (MSM)
Implementation Method 3
target intracellular iron and calcium, thereby slowing down cataract progression... reducing light-scattering particles in the lens
Data Source
AI summary
A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second permeation enhancer such as propylene glycol, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.